Literature DB >> 1533553

Cyanide toxicity from sodium nitroprusside: risks and management.

J P Rindone1, E P Sloane.   

Abstract

OBJECTIVE: To review the risks, manifestations, and treatment of cyanide toxicity from nitroprusside therapy. DATA SOURCES: All English case reports identified in Index Medicus (MEDLINE) of cyanide intoxication related to nitroprusside from 1970 to the present were reviewed. In addition, literature regarding the incidence, risks, and treatment of cyanide toxicity from nitroprusside is presented.
CONCLUSIONS: Numerous cases of cyanide toxicity associated with nitroprusside have been reported. The overall incidence appears to be infrequent; however, certain patients may be at high risk. Risk factors may include hypoalbuminemia, cardiopulmonary bypass procedures, or the administration of moderate to high doses of nitroprusside. Treatment of cyanide toxicity requires the cessation of nitroprusside and, for severe toxicity, use of the cyanide antidote kit. Cyanide toxicity from nitroprusside may be prevented by concomitant administration of sodium thiosulfate infusions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533553     DOI: 10.1177/106002809202600413

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  14 in total

1.  Note of caution for the use of sodium nitroprusside in neonatal hypertension.

Authors:  Christian von Schnakenburg; Marcus Krüger
Journal:  Pediatr Nephrol       Date:  2004-08-25       Impact factor: 3.714

2.  Lactic acidosis caused by sodium nitroprusside in a newborn with congenital heart disease.

Authors:  Sascha Meyer; Ali Baghai; Nieves-Lucia Sailer; Sven Gottschling
Journal:  Eur J Pediatr       Date:  2005-01-22       Impact factor: 3.183

3.  Central nervous system toxicity of sodium nitroprusside in treatment of patients with aortic dissection.

Authors:  Xueyuan Huang; Lingbo Hou; Jiarong Tang; Yanmei Zhang; Fuqiong Chen; Daowen Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

4.  Cyanide toxicity in juvenile pigs and its reversal by a new prodrug, sulfanegen sodium.

Authors:  Kumar G Belani; Harpreet Singh; David S Beebe; Preeta George; Steven E Patterson; Herbert T Nagasawa; Robert Vince
Journal:  Anesth Analg       Date:  2012-03-05       Impact factor: 5.108

5.  Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase.

Authors:  Thomas W Miller; Jeff S Isenberg; David D Roberts
Journal:  Br J Pharmacol       Date:  2010-03-03       Impact factor: 8.739

Review 6.  Development of sulfanegen for mass cyanide casualties.

Authors:  Steven E Patterson; Bryant Moeller; Herbert T Nagasawa; Robert Vince; Daune L Crankshaw; Jacquie Briggs; Michael W Stutelberg; Chakravarthy V Vinnakota; Brian A Logue
Journal:  Ann N Y Acad Sci       Date:  2016-06-16       Impact factor: 5.691

7.  Cyanide poisoning in the post-transplantation patient-a cautionary tale.

Authors:  Catherine Quinlan; Denis Gill; Mary Waldron; Atif Awan
Journal:  Pediatr Nephrol       Date:  2008-08-07       Impact factor: 3.714

8.  Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells.

Authors:  Shaquria P Adderley; Chintamani N Joshi; Danielle N Martin; David Anthony Tulis
Journal:  Front Pharmacol       Date:  2012-02-07       Impact factor: 5.810

9.  New treatment options for hypertension during acute ischemic or hemorrhagic stroke.

Authors:  J David Spence
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-06

Review 10.  Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow.

Authors:  Natasha M Rogers; Franziska Seeger; Elsa D Garcin; David D Roberts; Jeffrey S Isenberg
Journal:  Front Physiol       Date:  2014-04-04       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.